University Hospitals - Seidman Cancer Center
Welcome,         Profile    Billing    Logout  
 24 Trials 
80 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Lee, Richard K
NCT03824119: Postpartum NSAIDS and Maternal Hypertension

Recruiting
4
200
US
Ibuprofen 600 mg, Standard Postpartum Care, Standard Postpartum Care without NSAIDs
University of Southern California
Preeclampsia, Gestational Hypertension, Superimposed Preeclampsia, Chronic Hypertension in Obstetric Context
12/22
12/22
NRG-BN003, NCT03180268: Observation or Radiation Therapy in Treating Patients With Newly Diagnosed Grade II Meningioma That Has Been Completely Removed by Surgery

Recruiting
3
148
Canada, Japan, US, RoW
Clinical Observation, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation
NRG Oncology, National Cancer Institute (NCI)
Grade II Meningioma, Intracranial Meningioma
06/27
08/27
NRG-HN005, NCT03952585: De-intensified Radiation Therapy With Chemotherapy (Cisplatin) or Immunotherapy (Nivolumab) in Treating Patients With Early-Stage, HPV-Positive, Non-Smoking Associated Oropharyngeal Cancer

Active, not recruiting
2/3
384
Canada, US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Fludeoxyglucose F-18, 18FDG, FDG, Fludeoxyglucose (18F), fludeoxyglucose F 18, Fludeoxyglucose F18, Fluorine-18 2-Fluoro-2-deoxy-D-Glucose, Fluorodeoxyglucose F18, Image Guided Radiation Therapy, IGRT, image-guided radiation therapy, Image-Guided Radiotherapy, Intensity-Modulated Radiation Therapy, IMRT, Intensity modulated radiation therapy (procedure), Intensity Modulated RT, Intensity-Modulated Radiotherapy, Radiation, Intensity-Modulated Radiotherapy, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI, Nivolumab, ABP 206, BCD-263, BMS 936558, BMS-936558, BMS936558, CMAB819, MDX 1106, MDX-1106, MDX1106, NIVO, Nivolumab Biosimilar ABP 206, Nivolumab Biosimilar BCD-263, Nivolumab Biosimilar CMAB819, ONO 4538, ONO-4538, ONO4538, Opdivo, Positron Emission Tomography, Medical Imaging, Positron Emission Tomography, PET, PET Scan, Positron emission tomography (procedure), Positron Emission Tomography Scan, Positron-Emission Tomography, proton magnetic resonance spectroscopic imaging, PT, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
National Cancer Institute (NCI), NRG Oncology
Basaloid Squamous Cell Carcinoma, Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Oropharyngeal Squamous Cell Carcinoma, Papillary Squamous Cell Carcinoma, Pathologic Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Squamous Cell Carcinoma
03/24
12/25
CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting
2/3
1912
Canada, US
Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month
NRG Oncology, Natera, Inc., National Cancer Institute (NCI)
Stage III Colon Cancer
03/29
03/30
NCT04824937: Telaglenastat + Talazoparib In Prostate Cancer

Not yet recruiting
2
30
US
Telaglenastat, CB 839, Talazoparib, Taken orally
Massachusetts General Hospital, Calithera Biosciences, Inc, Pfizer, Prostate Cancer Foundation
Prostate Cancer Metastatic
12/21
12/21
I-SPY_COVID, NCT04488081: I-SPY COVID-19 TRIAL: An Adaptive Platform Trial for Critically Ill Patients

Recruiting
2
1500
US
Remdesivir, GS-5734, Imatinib Mesylate, Dexamethasone, Cenicriviroc, Icatibant, Firazyr, Apremilast, Otezla, dornase alfa, Pulmozyme, Celecoxib, celebrex, Famotidine, Pepcid, IC14, Aviptadil, Zyesami, narsoplimab, OMS721, Cyproheptadine, periactin, Cyclosporine, CsA
QuantumLeap Healthcare Collaborative, University of California, San Francisco, University of Pennsylvania, Emory University, University of Alabama at Birmingham, University of Colorado, Denver, University of Southern California, Yale University, Wake Forest University Health Sciences, Sanford Health, Long Beach Memorial Medical Center, Georgetown University, University of California, Davis, Hoag Memorial Hospital Presbyterian, Main Line Health, DHR Health Institute for Research and Development, University of California, Irvine, Corewell Health, Kaiser Permanente, University of Michigan, West Virginia University, University of Miami, University Hospitals Cleveland Medical Center, Virtua Health, M.D. Anderson Cancer Center
COVID-19
07/28
07/30
KEYNOTE B36, NCT04892472: EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

Recruiting
2
100
US
NovoTTF-200T, Pembrolizumab (MK-3475) 200 mg
NovoCure GmbH, Merck Sharp & Dohme LLC
Non-small Cell Lung Cancer
07/24
12/26
NCT06041789: Effect of Acetylcholinesterase Inhibitors on Bone Metabolism

Recruiting
2
45
US
Donepezil, Placebo
Duke University, National Institute on Aging (NIA)
Osteoporosis
06/25
06/25
NCT06731894: Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Not yet recruiting
2
120
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Cannabidiol, CBD, CBD Oil, Epidiolex, GWP42003-P, Dronabinol, (-)-.DELTA.9-Tetrahydrocannabinol, Abbott 40566, Delta(9)-Tetrahydrocannibinol, Delta-9-Tetrahydrocannabinol, Delta-9-THC, Delta9-THC, Marinol, SP 104, SP-104, SYNDROS, Tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol, Tetrahydrocannabinol, THC, Placebo Administration, Survey Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
10/26
10/26
NCT04014205: A Study of Tyrosine Kinase Inhibitor Orelabrutinib (ICP-022) in Patients With r/r B-Cell Malignancies

Active, not recruiting
1/2
81
Europe, US, RoW
Orelabrutinib (ICP-022)
Beijing InnoCare Pharma Tech Co., Ltd.
Part 1：r/r B-cell Malignancies, Part 2：B-cell Malignancies
12/23
01/25
CELLO-1, NCT04179864 / 2019-003649-14: A Study of Tazemetostat With Enzalutamide or Abiraterone/Prednisone in Participants With Advanced Prostate Cancer

Checkmark Data from CELLO-1 trial for CRPC at SUO 2022
Dec 2022 - Dec 2022: Data from CELLO-1 trial for CRPC at SUO 2022
Checkmark Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Sep 2021 - Sep 2021: Safety data from P1b portion of P1b/2 trial in combination with enzalutamide or with abiraterone/prednisone for CRPC at ESMO 2021
Terminated
1/2
102
Europe, US
Tazemetostat, EPZ-6438, E7438, IPN60200, Abiraterone/prednisone, Zytiga, Enzalutamide, Xtandi
Epizyme, Inc.
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
11/24
11/24
KEYNOTE-E58, NCT04041310: Nous-209 Genetic Vaccine for the Treatment of Microsatellite Unstable Solid Tumors

Active, not recruiting
1/2
115
Europe, Canada, US
GAd-209-FSP low dose, MVA-209-FSP low dose, GAd-209-FSP high dose, MVA-209-FSP high dose, GAd20-209-FSP, RP2D, MVA-209-FSP, RP2D, KEYTRUDA®, pembrolizumab
Nouscom SRL, Merck Sharp & Dohme LLC
Solid Tumor, Adult
04/25
11/26
NCT04524962: Study of Descartes-30 in Acute Respiratory Distress Syndrome

Terminated
1
12
US
Descartes 30
Cartesian Therapeutics, National Heart, Lung, and Blood Institute (NHLBI)
Acute Respiratory Distress Syndrome, Covid19
09/22
09/23
NCT05672342: Phytocannabinoids for the Treatment of Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors

Withdrawn
1
120
US
Cannabidiol, CBD, CBD Oil, Epidiolex, GWP42003-P, Delta-8-Tetrahydrocannabinol, .DELTA.8-TETRAHYDROCANNABINOL, delta-8-THC, Placebo Administration, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Breast Carcinoma, Chemotherapy-Induced Peripheral Neuropathy, Colon Carcinoma
10/25
10/25
LIBRA, NCT04270799: Lung Nodule Imaging Biobank for Radiomics and AI Research

Recruiting
N/A
1000
Europe
Machine Learning Classification
Royal Marsden NHS Foundation Trust, RM Partners West London Cancer Alliance, Royal Brompton & Harefield NHS Foundation Trust, University College London Hospitals, Imperial College Healthcare NHS Trust, Lewisham and Greenwich NHS Trust, King's College Hospital NHS Trust, Epsom and St Helier University Hospitals NHS Trust, Institute of Cancer Research, United Kingdom, Guy's and St Thomas' NHS Foundation Trust, UCLH Biomedical Research Centre
Lung Cancer, Pulmonary Nodule, Multiple, Pulmonary Nodule, Solitary, Lung Neoplasms
08/21
08/21
NCT01961843: Abiraterone Acetate for Castrate Resistant Prostate Cancer

Active, not recruiting
N/A
40
US
Abiraterone, Abiraterone acetate, Zytiga, Prednisone
Massachusetts General Hospital
Prostate Cancer
06/24
12/24
NCT01961713: Circulating Tumor Cell Analysis in Patients With Localized Prostate Cancer Undergoing Prostatectomy

Recruiting
N/A
200
US
Massachusetts General Hospital, Prostate Cancer Foundation Clinical Research Consortium
Prostate Cancer
12/25
12/25
NCT02862158: Frequency Doubling Technology (FDT) Mobile Visual Field Testing

Recruiting
N/A
500
US
FDT visual field, Standard HVF
University of Miami
Glaucoma
11/22
11/22
AI-SONAR, NCT05375591: AI & Radiomics for Stratification of Lung Nodules After Radically Treated Cancer

Recruiting
N/A
1000
Europe
Non-Interventional Study
Royal Marsden NHS Foundation Trust, Institute of Cancer Research, United Kingdom, National Institute for Health Research, United Kingdom, Royal Brompton & Harefield NHS Foundation Trust, Royal Marsden Partners Cancer Alliance, Imperial College London, Oxford University Hospitals NHS Trust, National Heart and Lung Institute
Indeterminate Pulmonary Nodules, Lung Metastases, Second Primary Cancer, Lung Cancer
11/22
11/26
NCT04957433: 'Lung Health Check' Biomarker Study

Recruiting
N/A
1000
Europe
Blood Specimen, Sputum Specimen
Royal Marsden NHS Foundation Trust, Royal Brompton & Harefield NHS Foundation Trust, Imperial College London, Royal Marsden Partners Cancer Alliance
Lung Cancer, Cancer
12/23
12/23
SCOOT, NCT05368298: Sample Collection for DART

Recruiting
N/A
5000
Europe
University of Oxford, Innovate UK, Optellum, National Institute for Health Research, United Kingdom, Cancer Research UK, GE Healthcare, RNA Guardian, Roche Diagnostics GmbH
Lung Cancer
02/25
02/25
PILLCAM, NCT06712095: Video Capsule Examination in Patients With Lynch Syndrome

Recruiting
N/A
25
Europe
Video capsule investigation, Colonoscopy
Royal Marsden NHS Foundation Trust, King's College London
Lynch Syndrome, Li Fraumeni Syndrome, PTEN Hamartoma Syndrome, FAP, MUTYH Biallelic Mutation, STK11 Mutation, CDH1 Gene Mutation, CHEK2 Gene Mutation, BMPR1A Gene Mutation, SMAD4 Gene Mutation
10/25
10/25
DOLCE, NCT05389774: Determining the Impact of Optellum's Lung Cancer Prediction Solution

Recruiting
N/A
2000
Europe
Nottingham University Hospitals NHS Trust, Optellum Ltd.
AI (Artificial Intelligence), Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple, Lung Cancer
01/25
01/25
NCT06500377: Comparing the Impact of Four Types of Meditation Practices for Relaxation in Cancer Survivors

Recruiting
N/A
44
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Meditation Therapy, Meditation, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
06/26
06/26
NCT03615794: A Study of Pregnant and Postpartum Women With and Without Mood Disorders

Active, not recruiting
N/A
400
US
Johns Hopkins University, University of Virginia
Bipolar Disorder, Major Depressive Disorder, Postpartum Depression, Postpartum Psychosis
01/24
12/25
NCT06581211: Aromatherapy Oil Associated for Managing Anxiety and Pain During Bone Marrow Biopsy Procedures

Recruiting
N/A
45
US
Aromatherapy and Essential Oils, Aromatherapy, Electronic Health Record Review, Jojoba Oil, Lavender Oil, Common Lavender Oil, English Lavender Oil, Lavandula officinalis Flowering Top Oil, Questionnaire Administration
City of Hope Medical Center, National Cancer Institute (NCI)
Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
12/28
12/28
NCT05876676: RDC Biomarker Study

Not yet recruiting
N/A
1000
NA
Royal Marsden NHS Foundation Trust
Cancer
04/25
04/26
NIMBLE, NCT05432739: Nodule IMmunophenotyping Biomarker for Lung Cancer Early Diagnosis Study

Recruiting
N/A
500
Europe
Royal Marsden NHS Foundation Trust, Royal Brompton & Harefield NHS Foundation Trust, Royal Marsden Partners West London Cancer Alliance, Imperial College London, University College London Hospitals, Lewisham and Greenwich NHS Trust, Guy's and St Thomas' NHS Foundation Trust, Epsom and St Helier University Hospitals NHS Trust, King's College Hospital NHS Trust, University College London (UCL) Cancer Institute, Institute of Cancer Research, United Kingdom, Francis Crick Institute, Royal Sussex County Hospital
Lung Cancer
01/26
01/31
AnswerLine, Cancer
NCT04754399: Cannabidiol (CBD) for Treatment of Aromatase Inhibitor-Associated Arthralgias

Completed
2
40
US
Cannabidiol (CBD), Epidiolex
University of Michigan Rogel Cancer Center, American Society of Clinical Oncology
Arthralgia, Breast Cancer
10/23
10/23
VEnT, NCT06617455: Fezolinetant for the Improvement of Vasomotor Symptoms in Breast Cancer Patients Taking Endocrine Therapy, VENT Trial

Not yet recruiting
2
36
US
Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Fezolinetant, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Questionnaire Administration
University of Michigan Rogel Cancer Center, The Breast Cancer Research Foundation
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Ductal Carcinoma In Situ, Localized Breast Carcinoma
09/26
12/26
CuSToMIze, NCT05894083: A Phase II Study for p16+ Oropharyngeal Cancer PerSonalized De-escalation Treatment at University of MIchigan

Recruiting
2
150
US
Surgery, Chemoradiation, Observation, Post-operative radiation
University of Michigan Rogel Cancer Center
Oropharyngeal Cancer, Squamous Cell Carcinoma of the Oropharynx
04/25
04/29
FAALCON, NCT04748042: Focal Radiation With Pulsed Systemic Therapy of Abiraterone, Androgen Deprivation Therapy (ADT), Lynparza Towards Castration Sensitive Oligometastatic Prostate Cancer

Recruiting
2
29
US
Abiraterone, Zytiga, Prednisone, External Beam Radiotherapy, Androgen Deprivation Therapy (ADT), Olaparib, Lynparza, AZD2281
University of Michigan Rogel Cancer Center
Prostate Cancer, Castrate Sensitive Prostate Cancer, Oligometastatic Disease
05/25
05/25
NCT04845035: Pediatric-Inspired Chemotherapy Plus Tyrosine Kinase Inhibitor in Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Withdrawn
2
23
US
Dasatinib, Ponatinib, Berlin-Frankfurt-Münster Chemotherapy, Methotrexate and Cytarabine
University of Michigan Rogel Cancer Center, Takeda
Acute Lymphoblastic Leukemia
01/26
01/29
NCT04858256: Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms

Recruiting
2
100
US
Pacritinib
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Cancer Institute (NCI)
T-Cell Neoplasm, Lymphoproliferative Disorders
11/27
11/28
AVB500-PC-005, NCT04983407: Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma

Terminated
1b/2
34
US
batiraxcept, AVB-S6-500, Nab paclitaxel, Abraxane, Gemcitabine
Aravive, Inc.
Pancreatic Adenocarcinoma
08/23
08/23
NCT03520075 / 2018-004568-72: Study of ASTX029 in Subjects With Advanced Solid Tumors

Active, not recruiting
1/2
190
Europe, US
ASTX029
Taiho Oncology, Inc.
Solid Tumor, Adult
08/24
12/25
BilT-04, NCT04203160: Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer

Completed
1/2
75
US
CPI 613, Devimistat®, Gemcitabine, Gemzar®, Cisplatin, CDDP, Platinol®, NSC-119875
University of Michigan Rogel Cancer Center
Biliary Tract Cancer
04/24
04/24
NCT03559049: Rucaparib and Pembrolizumab for Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer

Active, not recruiting
1/2
25
US
Pembrolizumab, Pemetrexed, Carboplatin, Rucaparib
University of Michigan Rogel Cancer Center, Merck Sharp & Dohme LLC, Clovis Oncology, Inc.
Stage IV Non-small Cell Lung Cancer
01/25
01/28
CAPS, NCT03781986: APG-115 in Salivary Gland Cancer Trial

Active, not recruiting
1/2
41
US
APG-115, Carboplatin
University of Michigan Rogel Cancer Center, Ascentage Pharma Group Inc.
Malignant Salivary Gland Cancer, Salivary Gland Cancer
06/25
12/25
NCT06616155: Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Not yet recruiting
1/2
39
US
Biopsy, BIOPSY_TYPE, Bx, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Enzalutamide, ASP9785, MDV 3100, MDV-3100, MDV3100, Xtandi, Ruxolitinib, INCB 018424, INCB-018424, INCB-18424, INCB18424, Oral JAK Inhibitor INCB18424
University of Michigan Rogel Cancer Center, Incyte Corporation
Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
03/27
03/29
NCT05902988: A Phase I/II Study of VLS-1488 in Subjects with Advanced Cancer

Recruiting
1/2
120
US
VLS-1488
Volastra Therapeutics, Inc.
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Gastric Adenocarcinoma, Colorectal Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Transitional Cell Carcinoma of Bladder, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
12/25
06/26
LiFFT, NCT05918640: Lurbinectedin in FET-Fused Tumors

Recruiting
1/2
56
US
Lurbinectedin
Children's Hospital of Philadelphia, Jazz Pharmaceuticals, Stand Up To Cancer
Ewing Sarcoma, Desmoplastic Small Round Cell Tumor, Pediatric Cancer, Undifferentiated Sarcoma
07/26
07/28
ASCLEPIuS, NCT04194554: A Multi-Center Trial of Androgen Suppression With Abiraterone Acetate, Leuprolide, PARP Inhibition and Stereotactic Body Radiotherapy in Prostate Cancer

Active, not recruiting
1/2
102
US
Niraparib, Leuprolide, Abiraterone Acetate, Stereotactic body radiotherapy (SBRT), Ultra-hypofractionated radiotherapy
University of Michigan Rogel Cancer Center, Janssen Scientific Affairs, LLC
Prostate Cancer
11/26
05/27
NCT04703920: Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer

Active, not recruiting
1
26
US
Talazoparib, Belinostat
University of Michigan Rogel Cancer Center, Pfizer, Acrotech Biopharma Inc.
Metastatic Breast Cancer, Metastatic Castration-resistant Prostate Cancer, Metastatic Ovarian Carcinoma
12/24
12/24
NCT04477200: Mycophenolate Mofetil Combined With Radiation Therapy in Glioblastoma

Recruiting
1
68
US
Mycophenolate Mofetil, MMF, Radiation Therapy, RT, Re-resection (as part of standard of care), Temozolomide, TMZ
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Recurrent Glioblastoma, Recurrent Gliosarcoma, Recurrent Astrocytoma, Grade IV, Newly Diagnosed Glioblastoma, Newly Diagnosed Gliosarcoma, Newly Diagnosed Astrocytoma, Grade IV
10/25
10/27
NCT04852471: Improving Quality of Life Using Patient Reported Outcomes Measures Post-operative Via Text Messaging

Completed
N/A
102
US
Standard Post-Operative Counseling + FACT-G, PROM symptom tracker
University of Michigan Rogel Cancer Center
Gynecologic Cancer
05/23
05/23
NCT05140252: Avoiding Low-value Treatments in Older Women With Early-stage Breast Cancer: Piloting a Patient Decision Aid

Completed
N/A
22
US
Breast cancer decision aid
University of Michigan Rogel Cancer Center
Breast Cancer
09/23
09/23
NCT05704790: Feasibility and Acceptability of Brief, Telehealth Cognitive Compensatory Training for Pediatric Cancer Patients

Completed
N/A
26
US
Cognitive Compensatory Training
University of Michigan Rogel Cancer Center
Pediatric Cancer
07/24
07/24
NCT05764005: Optimizing Active Surveillance in Low-Risk Prostate Cancer: a Pilot Study

Completed
N/A
40
US
web-based tool (MAP- Management of Active surveillance in Prostate Cancer), MUSIC website
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Prostate Cancer
03/24
03/24
NCT05583422: Evaluating a Pharmacogenetic Testing Panel in Patients Suspected to be at Increased Risk for Pharmacogenetics-related AEs While Receiving Fluoropyrimidine or Irinotecan Therapy

Active, not recruiting
N/A
16
US
DPYD or UGT1A1 variants
University of Michigan Rogel Cancer Center
Cancer
12/25
12/25
NCT05965180: Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe

Recruiting
N/A
20
US
Fine Needle Photoacoustic Probe
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Prostate Cancer
10/25
10/25
MiGHT, NCT05162846: Methods for Increasing Genetic Testing Uptake in Michigan

Active, not recruiting
N/A
831
US
Publicly available genetic testing resources, Virtual genetics navigator, Motivational interviewing (MI)
University of Michigan Rogel Cancer Center, National Cancer Institute (NCI)
Breast Cancer, Colorectal Cancer, Ovarian Cancer, Prostate Cancer, Pancreatic Cancer, Endometrial Cancer, History of Cancer
12/26
12/26
NCT05578898: CLEAR Care Companion Application

Completed
N/A
28
US
CLEAR Care Companion (CC) application
University of Michigan Rogel Cancer Center
Bladder Cancer, Radical Cystectomy
07/24
07/24
B-REP, NCT06100263: Breast Cancer Resiliency Through Exercise Program

Recruiting
N/A
200
US
Individualized exercise program, Control Arm
University of Michigan Rogel Cancer Center
Breast Cancer Female
12/26
12/26
NCT05945121: Prehabilitation Program to Improve Cardiac Reserve in High-Risk Patients Undergoing Hematopoietic Stem Cell Transplantation

Recruiting
N/A
10
US
Cardio-oncology program
University of Michigan Rogel Cancer Center, National Institutes of Health (NIH), National Heart, Lung, and Blood Institute (NHLBI)
Hematopoietic Stem Cell Transplant
08/27
08/27
NCT00843375: Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas

Recruiting
N/A
1200
Canada, US, RoW
University of Michigan Rogel Cancer Center, Early Detection Research Network, Clinical Genomics Pathology, VolitionRx, Department of Health and Human Services, Great Lakes New England Clinical Validation Center, National Cancer Institute (NCI)
Colonic Neoplasms
03/28
03/28
NCT05866302: Parametric Response Mapping (PRM) for the Detection of Chronic Lung Injury in Hematopoietic Cell Transplant Recipients

Recruiting
N/A
375
US
University of Michigan Rogel Cancer Center, National Heart, Lung, and Blood Institute (NHLBI)
Chronic Lung Disease, Hematopoietic Cell Transplantation, Graft Versus Host Disease
05/28
05/28
Bajor, David
A021806, NCT04340141: Testing the Use of the Usual Chemotherapy Before and After Surgery for Removable Pancreatic Cancer

Recruiting
3
352
Canada, US
Oxaliplatin, Irinotecan Hydrochloride, Leucovorin Calcium, Fluorouracil, Resection, Questionnaire Administration
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI)
Pancreatic Adenosquamous Carcinoma, Resectable Pancreatic Adenocarcinoma, Pancreatic Cancer
01/26
11/30
NCT02861300: CB-839 + Capecitabine in Solid Tumors and Fluoropyrimidine Resistant PIK3CA Mutant Colorectal Cancer

Completed
1/2
50
US
CB-839, Capecitabine, Xeloda
David Bajor, MD
Colorectal Cancer, Colon Cancer, Rectal Cancer, Solid Tumor
01/23
01/23
NCT03699319: CPI-613 in Combination With Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Completed
1/2
49
US
CPI 613, 6, 8-bis-benzylsulfanyloctanoic acid, Oxaliplatin, Eloxatin, Irinotecan, Camptosar, 5-flurouracil, 5FU, Folinic acid, Leucovorin, Calcium folinate, FA
David Bajor, MD
Pancreatic Cancer
09/24
09/24
BilT-04, NCT04203160: Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer

Completed
1/2
75
US
CPI 613, Devimistat®, Gemcitabine, Gemzar®, Cisplatin, CDDP, Platinol®, NSC-119875
University of Michigan Rogel Cancer Center
Biliary Tract Cancer
04/24
04/24
NCT06322693: A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER)

Recruiting
1
475
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
GlaxoSmithKline
Neoplasms
08/25
02/27
NCT05209074: Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma

Recruiting
1
16
US
Ivosidenib, mFOLFIRINOX
Case Comprehensive Cancer Center
Pancreatic Ductal Adenocarcinoma, Resectable Pancreatic Cancer
07/26
12/26
AMBER, NCT02817633: A Study of TSR-022 in Participants With Advanced Solid Tumors

Hourglass Oct 2019 - Mar 2020 : From AMBER trial
Checkmark From AMBER trial at SITC 2018 [screenshot]
Nov 2018 - Nov 2018: From AMBER trial at SITC 2018 [screenshot]
Checkmark From AMBER trial in combination with TSR-022 at SITC 2018
Nov 2018 - Nov 2018: From AMBER trial in combination with TSR-022 at SITC 2018
Recruiting
1
447
Europe, US, RoW
TSR-022, Nivolumab, TSR-042, TSR-033, Docetaxel, Pemetrexed, Cisplatin, Carboplatin
Tesaro, Inc.
Neoplasms
04/25
04/27
TOS-358-001, NCT05683418: A Study to Evaluate the Safety and Tolerability of TOS-358 in Adults with Select Solid Tumors

Recruiting
1
241
Europe, US
TOS-358
Totus Medicines
Squamous Cell Carcinoma of Head and Neck, Urothelial Carcinoma, Endometrial Cancer, HR+/HER2-negative Breast Cancer
12/25
12/25
GARNET, NCT02715284: Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors

Checkmark MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Dec 2022 - Dec 2022: MFDS approved in Korea in adult patients with recurrent or advanced dMMR/MSI-H 2L endometrial cancer
Checkmark Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Sep 2022 - Sep 2022: Result from GARNET trial for dMMR endometrial cancer and other solid tumors at ESMO 2022
Checkmark Approved for recurrent or advanced endometrial cancer
More
Recruiting
1
740
Europe, Canada, US, RoW
Dostarlimab
Tesaro, Inc.
Neoplasms
05/26
10/27
SGNEGFRd2-001, NCT05983133: A Study of SGN-EGFRd2 in Advanced Solid Tumors

Recruiting
1
275
Europe, US
SGN-EGFRd2
Seagen Inc.
Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of the Head and Neck, Pancreatic Ductal Adenocarcinoma
07/27
09/28
NCT05238467: Immunological Responses of COVID-19 Vaccination

Completed
N/A
42
US
COVID antibody titers in the blood
University Hospitals Cleveland Medical Center
Cancer; Chemotherapy
02/23
02/23
Barata, Pedro
PROBE, NCT04510597: Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the Trial

Recruiting
3
364
US
Cytoreductive Nephrectomy, Active Comparator
SWOG Cancer Research Network, National Cancer Institute (NCI)
Metastatic Clear Cell Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/33
07/33
NCT06312670: Combining EPI-7386 with Enzalutamide and Androgen Deprivation Therapy for Metastatic Hormone-Sensitive Prostate Cancer

Active, not recruiting
2
13
US
EPI-7386, Enzalutamide, Androgen Deprivation Therapy (ADT)
Pedro Barata, MD, MSc, ESSA Pharma Inc.
Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Prostate Cancer, Prostate Adenocarcinoma
03/26
03/26
NCT06738303: Cabazitaxel +/- Carboplatin vs 177Lu-PSMA-617 in Metastatic Castrate-resistant Prostate Cancer

Not yet recruiting
2
44
US
Cabazitaxel and carboplatin, Lu-PSMA-617, Pluvicto
Case Comprehensive Cancer Center
Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
12/26
12/26
CASCARA, NCT03934840: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone

Active, not recruiting
2
22
US
Cabazitaxel, Carboplatin, Abiraterone, Prednisone
Masonic Cancer Center, University of Minnesota
Prostate Cancer
06/23
05/25
OPTIC RCC, NCT05361720: Genetic Testing to Select Therapy for the Treatment of Advanced or Metastatic Kidney Cancer, Study

Recruiting
2
54
US
Cabozantinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo
Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI), United States Department of Defense
Advanced Clear Cell Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8
07/25
07/26
NCT05588609: Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers

Active, not recruiting
2
90
US
Afatinib Oral Tablet, GILOTRIF®, GIOTRIF®, Enzalutamide Pill, XTANDI®, Abiraterone acetate tablets, ZYTIGA®, MCLA-128, Zenocutuzumab
Merus N.V.
NSCLC Harboring NRG1 Fusion, Metastatic Castration-resistant Prostate Cancer
10/25
03/26
NCT04267120: Lenvatinib (LEN) in Combination With Pembrolizumab (KEYtruda) in Subjects With Locally Advanced or Metastatic Non-clear Cell Renal Cell Carcinoma (The LENKYN Trial)

Active, not recruiting
2
11
US
Lenvatinib, Lenvima, Lenvanix, Pembrolizumab, Keytruda, MK-3475, Research blood collection
Washington University School of Medicine, Merck Sharp & Dohme LLC
Renal Cell Carcinoma
07/24
12/25
PAPMET2, NCT05411081: Testing Cabozantinib With or Without Atezolizumab in Patients With Advanced Papillary Kidney Cancer, Trial

Recruiting
2
200
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG 7446, RG-7446, RG7446, RO 5541267, RO-5541267, RO5541267, Tecentriq, Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Scan, Bone Scintigraphy, Cabozantinib S-malate, BMS-907351, Cabometyx, Cometriq, XL 184, XL-184, XL184, Computed Tomography, CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, Computerized Tomography (CT) scan, CT, CT Scan, tomography, Magnetic Resonance Imaging, Magnetic Resonance, Magnetic Resonance Imaging (MRI), Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, MRIs, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging, sMRI, Structural MRI
National Cancer Institute (NCI)
Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8
07/27
07/27
SAMURAI, NCT05327686: Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, Study

Recruiting
2
240
US
Avelumab, Bavencio, MSB-0010718C, MSB0010718C, Axitinib, AG-013736, AG013736, Inlyta, Cabozantinib, Ipilimumab, Anti-Cytotoxic T-Lymphocyte-Associated Antigen-4 Monoclonal Antibody, BMS-734016, Ipilimumab Biosimilar CS1002, MDX-010, MDX-CTLA4, Yervoy, Lenvatinib, E7080, ER-203492-00, Multi-Kinase Inhibitor E7080, Nivolumab, BMS-936558, CMAB819, MDX-1106, NIVO, Nivolumab Biosimilar CMAB819, ONO-4538, Opdivo, Pembrolizumab, Keytruda, Lambrolizumab, MK-3475, SCH 900475, Stereotactic Ablative Radiotherapy, SABER, SABR, SBRT, Stereotactic Ablative Radiation Therapy
NRG Oncology, National Cancer Institute (NCI)
Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell Carcinoma
06/28
06/32
CombTMS, NCT06500533: Combining RTMS and TDCS in Depression: an Exploratory Clinical Trial

Recruiting
N/A
40
Europe
rTMS combined with tDCS
Regionspsykiatrien Gødstrup, Regionspsykiatrien Randers
Major Depression, Treatment Resistant Depression
12/27
12/27
IRONMAN, NCT03151629: International Registry for Men With Advanced Prostate Cancer

Recruiting
N/A
5000
Europe, Canada, US, RoW
Standard of Care
Prostate Cancer Clinical Trials Consortium
Prostate Cancer
01/31
01/32
CC, UH Seidman
BilT-04, NCT04203160: Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer

Completed
1/2
75
US
CPI 613, Devimistat®, Gemcitabine, Gemzar®, Cisplatin, CDDP, Platinol®, NSC-119875
University of Michigan Rogel Cancer Center
Biliary Tract Cancer
04/24
04/24

Download Options